GREM1 and cancer: These results are consistent with the previous report that MGLL and GLRX are associated with immunity in cancer (Xiang et al., 2018; Chang et al., 2020) and GREM1 inhibits osteogenic differentiation, senescence, and BMP transcription of adipose-derived stem cells (Liu et al., 2021).